MedTrace Logo

Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction

NCT01810575 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-08-12

No results posted yet for this study

Summary

The purpose of this study is to assess the safety \& efficacy of a single dose of alprostadil cream with 2 concentrations of WC3036 compared to vehicle alone in men with erectile dysfunction.

Conditions

Interventions

DRUG

WC3036-11F/Alprostadil in Vehicle 2.5%

330 mcg alprostadil in 2.5% vehicle

DRUG

WC3036-12F/Alprostadil in Vehicle 0.5%

330 mcg alprostadil in 0.5% vehicle

DRUG

WC3036-13P/Vehicle Only 0.5%

100 mg cream vehicle 0.5%.

Sponsors & Collaborators

  • Warner Chilcott

    lead INDUSTRY

Principal Investigators

  • Vilma Sniukiene, MD · Warner Chilcott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01810575 on ClinicalTrials.gov